NumerixS Investment Technologies’s Ultragenyx Pharmaceutical RARE Stock Holding History

NumerixS Investment Technologies’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-599	Closed	-$47K	–	658
2020 Q2	$47K	Buy	+599	New	+$39.6K	0.01%	806
2019 Q3	–	Sell	-400	Closed	-$25K	–	1189
2019 Q2	$25K	Buy	+400	New	+$25.5K	0.01%	886
2018 Q2	–	Sell	-200	Closed	-$10K	–	1317
2018 Q1	$10K	Buy	+200	New	+$10.1K	﹤0.01%	981
2017 Q4	–	Sell	-5,300	Closed	-$282K	–	1318
2017 Q3	$282K	Sell	5,300 -1,200	-18%	-$71.1K	0.06%	400
2017 Q2	$404K	Sell	6,500 -3,900	-38%	-$235K	0.06%	403
2017 Q1	$705K	Buy	+10,400	New	+$793K	0.08%	302
2016 Q4	–	Sell	-3,700	Closed	-$262K	–	1298
2016 Q3	$262K	Sell	3,700 -8,500	-70%	-$543K	0.03%	601
2016 Q2	$597K	Buy	+12,200	New	+$789K	0.08%	341
2016 Q1	–	Sell	-2,551	Closed	-$286K	–	946
2015 Q4	$286K	Sell	2,551 -6,500	-72%	-$650K	0.04%	596
2015 Q3	$872K	Buy	+9,051	New	+$1.04M	0.1%	255

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

NumerixS Investment Technologies's RARE Position: Q3 2020 in Review

NumerixS Investment Technologies sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2020, closing a stake of 599 shares — an estimated $47K sold.

NumerixS Investment Technologies first reported a position in RARE in Q3 2015 and held it in 10 quarters. The position peaked at $872K in Q3 2015. 206 funds tracked by Wall St. Rank hold RARE as of Q3 2020.

NumerixS Investment Technologies reported no remaining Ultragenyx Pharmaceutical position as of Q3 2020 after selling out during the quarter.
NumerixS Investment Technologies sold 599 Ultragenyx Pharmaceutical shares in Q3 2020, an estimated $47K.
NumerixS Investment Technologies first reported a position in Ultragenyx Pharmaceutical in Q3 2015 and held it in 10 quarters.
NumerixS Investment Technologies's Ultragenyx Pharmaceutical position peaked at $872K in Q3 2015.
206 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2020.

Based on NumerixS Investment Technologies's 13F filing for Q3 2020.